Yara Bakım

Canlılarda kendilerini yenileme ve farklılaşma (plastisite) kabiliyeti bulunan hücrelere kök hücre denir. Bu konuda ilk önemli öngörü Alman bilim adamı Carl Rudolph Wirchow'un 1800'lü yılların başındaki "Omnis cellula e cellula = tüm hücreler başka hücrelerden gelişir" yaklaşımıdır. Bu yaklaşımdan yola cıkan  Harvest BMAC2 sistemi ile “point-of-care” olarak siz hekimlerimizin  kullanımına sunulmuştur.

Başlıca kullanım alanları Diabetik Ayaklar ve PAH (Perifer Arter Hastalığı)

LITARATUR

Stem cell and progenitor cell therapy in peripheral artery disease A critical appraisal Holger Lawall1; Peter Bramlage2; Berthold Amann3 1SRH-Klinikum Karlsbad-Langensteinbach, Angiology /Diabetology, Karlsbad, Germany; 2Institute for Cardiovascular Pharmacology und Epidemiology, Mahlow, Germany; 3Department of Internal Medicine, Franziskus Krankenhaus, Berlin Vascular Center, Berlin, Germany

Exploring new treatment strategies in patients with PAD is of utmost importance due to the high risk of major leg amputations and subsequent mortality if surgical or endovascular revascularisation has failed or is not possible. Autologous cell therapy using either BMMNC or PBMNC is a promising new treatment option for these patients, and clinical trials are very consistent in reporting clinical benefits including improvements of ABI, TcPO2,reduction of pain and reduced need for amputation.

Intraoperative Adjunctive Stem Cell Treatment in Patients with Critical Limb Ischemia Using a Novel Point-of-Care Device R. Kolvenbach,1 Carla Kreissig,1 Catherine Cagiannos,1 Rana Afifi,2,3 and Eva Schmaltz,1 Du¨sseldorf, Germany

We were able to show that the buffy coat preparation using a point-of-care system is a simple and fast method to enrich stem cells from BMAs. This automated system gives high recovery rates and good reproducibility